Abstract
Abstract Background Breast cancer is the most common malignant tumor among females around the world. It represents 1.7 million new cases per year and 25% of all types of cancers. Objectives Assessment of median overall survival in most aggressive subtypes of metastatic breast cancer (Triple –Ve and HER2+Ve) & to compare survival of metastatic HER2+Ve breast cancer in group received targeted versus that did not receive. Patient and Methods Multi institutional retrospective study for assessment of median OS in metastatic breast cancer for themost aggressive subtypes (HER2+Ve &Triple-Ve) at Ain Shams University Hospitals and El-Matarya teaching Hospital. Results Seventy-three metastatic breast cancer patients were included (31 Triple-Ve & 42 HER2+Ve) in the period between January 2014 and December 2016 At Ain Shams University Hospitals and El-Matarya teaching Hospital, we found that median OS for Triple negative group is 16 months with (95% CI 8.8- 23.6) , that for HER2+Ve group is 17 months with (95% CI 13.9 – 20.6) & for patients did not receive targeted therapy, median OS is 10 months (95% CI. 4-19.4,P.000). Conclusion From our study,we highlight that metastatic breast cancer patients (HER2+Ve subtype) &received targeted therapy, had the most superior survival outcome. so,targeted therapy must be included in first line treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
